The Lifestyle Disorders Market Outlook to 2014 Reimbursement issues, market dynamics, pipeline compounds
Lifestyle drugs have been a much debated segment of therapeutics for the pharmaceutical industry primarily due to the issues surrounding their inclusion in drug payment plans and diversion of resources for their research. These drugs have been a point of contention also because of a lack of clarity in defining them. For the purpose of this report, lifestyle diseases have been defined to include a range of indications that affect an individuals quality of life even though they may not be deemed a medical problem.
The market was led by the MDD therapeutic segment followed by hormonal contraceptives. The smallest indication among the lifestyle disorders was alcohol dependence. The overall market was $37.2bn but is forecast to decline, albeit with a low single digit CAGR over the 2008-14 period.
Lifestyle disorders are marked by slowed R&D process and limited investigational products though MDD reflects some differences to this scenario. Each of the therapeutic indication s considered in this report reflects a markedly different scenario that substantiates the investment case around them. For instance:
In the antidepressants market , the older antidepressants such as tricyclic s and monoamine oxidase inhibitors, have given way to agents that target metabolism, storage and release neurotransmitters such as serotonin and norepinephrine.
In case of obesity, compounds with novel mechanisms of action such as GLP-1 pathway, monoamine transmission, PTP-1B receptor and melanin system, are being investigated.
The hormonal contraceptives market is marked with little R&D that has led to gaps in contraceptive technology. The industry needs to invest in contraceptives with better side-effects profile to aid compliance.
Growth of the erectile dysfunction market would be determined by the market dynamics ensuing between Viagra, Cialis and Levitra.
In the smoking cessation market, growth prospects of the leading brands such as Pfizers Chantix, are likely to be determined by the markets response to the black box label warnings on neuropsychiatric effects, introduced in July 2009.
Key features of this report
Epidemiological analysis of the therapeutic segments and forecast prevalence over the period 2008-14
Forecasts and analysis of the key products in the lifestyle disorders market over the period 2008-14, across major classes of treatments
Overview of key events in the global lifestyle disorders market that have impacted treatment trends and sales potential.
Strategic and growth analysis of leading pharmaceutical corporations based on sales focus by drug class, currently marketed products and R&D product portfolios
Detailed analysis of the major classes of treatments across all the therapeutic segments analyzed in the report
Detailed analysis of the clinically differentiated products in the lifestyle disorders market pipeline and sales forecast of key R&D pipeline products in the global lifestyle disorders market